Compound Detail
CHEMBL4861471
ECLITASERTIB 🧪 Phase II
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
🧪 Phase II
Basic Information
| ChEMBL ID | CHEMBL4861471 |
| Name | ECLITASERTIB |
| Phase | Phase II |
| Structure Type | MOL |
| InChI Key | XUZICJHIIJCKQQ-ZDUSSCGKSA-N |
2
Targets
6
Activities
2
Assay Types
0
PK Parameters
1
Publications
5
Known Names
4
Indications
Molecular Properties
378.4
MW (Da)
0.94
ALogP
6
HBA
2
HBD
113.1
PSA (Ų)
0.70
QED
0
Ro5 Violations
4
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| Chirality | Single Enantiomer |
Indications
Colitis, Ulcerative Lupus Erythematosus, Cutaneous COVID-19 Severe Acute Respiratory Syndrome
Activity Summary
IC50 5 meas. best 7.43
EC50 1 meas. best 7.81
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| HT-29 CHEMBL384 | EC50 | 7.81 | 7.81 | 15.4 | 1 |
| Receptor-interacting serine/threonine-protein kinase 1 CHEMBL5464 | IC50 | 7.43 | 6.526 | 37.5 | 5 |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 33930803 | 10.1016/j.ejmech.2021.113484 | HT-29 | 2 |
Data from ChEMBL 36 via Core Engine